Clarus Securities analyst Noel Atkinson reported on TerrAscend on Thursday, saying a groundbreaking move to the TSX will bring new interest in the stock.
HLS Therapeutics has a 164 per cent upside, says Clarus cantechletter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cantechletter.com Daily Mail and Mail on Sunday newspapers.
Operator: Good afternoon. My name is Stephanie, and I will be your conference operator today. At this time, I’d like to welcome everyone to TerrAscend’s First Quarter 2023 Earnings Call.